August 30, 2019 / 5:38 AM / 5 months ago

Novartis begins hunt for piece of Roche's growing MS empire

ZURICH, Aug 30 (Reuters) - Novartis on Friday announced positive study results for its prospective multiple sclerosis drug ofatumumab that the Swiss drugmaker hopes will pose a stiff challenge to Roche’s medicine Ocrevus in a highly competitive market.

Novartis said ofatumumab, already approved as Arzerra to treat leukaemia, demonstrated superiority versus Sanofi’s Aubagio in two head-to-head late-stage MS studies. But Novartis’s true target with ofatumumab is Ocrevus, the $2.4 billion-per-year blockbuster that Roche has branded its most successful drug launch ever. (Reporting by John Miller; Editing by Michael Shields)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below